In addition, we identified immune-stromal-m6A-related HSPA7 as a novel prognostic risk factor in GBM patients; this gene plays a crucial role in immunophenotype determination, stromal activation, and oncogenic pathway activation and has a robust capacity to predict the ICB response. Here, METTL3 is linked to glioblastoma.